Despite the availability of several new systemic agents for psoriasis treatment, choosing the
right therapy in certain patient populations can be challenging. There are few up-to-date …

BACKGROUND: A task force of the National Psoriasis Foundation Medical Board was
convened to evaluate treatment options for pustular psoriasis. Meetings were held by …

BACKGROUND: Evidence-based recommendations for therapeutic decision making in
childhood psoriasis are lacking. OBJECTIVES: We sought to systematically review all …

Psoriasis is a chronic, immune-mediated, inflammatory skin disease, affecting 1–3% of the
white population. Although the existence of two psoriasis incidence peaks has been …

Objective Monogenic autoinflammatory diseases are disorders of Mendelian inheritance that
are characterized by mutations in genes that regulate innate immunity and whose typical …

Psoriasis is a common yet complex inflammatory dermatosis that may be seen in infants,
children, and adolescents. The clinical presentation and course may be quite variable, and …

Acitretin, an active metabolite of etretinate, is the most widely used systemic retinoid in the
treatment of psoriasis. There are several unique characteristics of this drug, which set it apart …

In 2008, a systematic review revealed that evidence‐based data on efficacy and safety of
treatments in paediatric psoriasis are scarce and with low level of evidence. In recent years …

There is lack of information and evidence‐based studies on the treatment of pediatric
pustular psoriasis. Previous reports have emphasized the limitations of the existing data and …

Background: There is a few evidence-based information regarding the efficacy and safety of
acitretin treatment in children with pustular psoriasis (PP). Objective: This study aimed to …